InMode reported Q2 revenue of $95.589 million, topping the $93 million IBES estimate, as U.S. aesthetic practices continue steady adoption of its RF microneedling (Morpheus8) and radiofrequency platforms. The beat reflects sustained demand for energy-based devices in the post-pandemic normalization of medspa traffic and pricing.
Devices & Tech
InMode Q2 Revenue Beats at $95.6M on Device Demand
RF microneedling and energy-device maker outpaces consensus on steady U.S. uptake.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
InMode beat consensus by $2.6M on steady U.S. device demand.
The result matters because InMode's guidance and execution directly track medspa capital deployment. Strong device revenue signals that practices are confident enough in patient flow and margins to invest in capital equipment—a leading indicator of sector health. Morpheus8's dominance in the RF microneedling category also reinforces the shift toward combination treatments (toxin + filler + device) as the standard revenue model in competitive markets.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.